|
| Indications |
L-Artem tablets are indicated for the treatment of P. falciparum malaria cases resistant to both chloroquine and sulphadoxine pyrimethamine combination.
|
|
| Pharmacological Class |
Antimalarial combination drug therapy.
|
|
| Pharmacological Properties |
Multi drug resistent Antimalarial treatment
|
|
| Mechanism of Action |
Both artemether and lumefantrine act as blood schizontocides. The site of antiparasitic action of both components of the combination is the food vacuole of the malarial parasite, where they are thought to interfere with the conversion of haem, a toxic intermediate produced during haemoglobin breakdown, to the non-toxic haemozoin, malaria pigment
|
|
| Side Effects |
Rare
|
|
| Contradictions |
L-Artem tablets are contraindicated:In those with hypersensitivity to the active substances or any of the excipients. In the first trimester of pregnancy. Patients with a family history of congenital prolongation of the QTc interval or sudden death or with any other clinical condition known to prolong the QTc interval such as patients with a history of symptomatic cardiac arrhythmias, patients with clinically relevant bradycardia or with severe cardiac disease, family history of sudden death, disturbances of electrolyte balance, e.g. hypokalaemia or hypomagnesaemia. L-Artem tablets are not indicated for prophylaxis of Malaria.
|
|
| Observations |
Use with caution in patients with severe hepatic or renal insufficiency and patients refusing food intake.
|
|
|